Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M William

Showing results (111-120 of 154) with videos related to

Pageof 16
Sort By:
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|June 19, 2015
Comparison of 2 Carmustine-Containing Regimens in the Rituximab Era: Excellent Outcomes Even in Poor-Risk PatientsPaolo F Caimi, Basem M William, Carlos H Silva Rondon, et al.
British Journal of Haematology|December 7, 2018
Phase I/II study of dasatinib and exploratory genomic analysis in relapsed or refractory non-Hodgkin lymphomaJayadev M Umakanthan, Javeed Iqbal, Connie L Batlevi, et al.
Lancet (London, England)|July 9, 2010
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trialAndrew Tutt, Mark Robson, Judy E Garber, et al.
Lancet (London, England)|July 9, 2010
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trialM William Audeh, James Carmichael, Richard T Penson, et al.
Neurology|October 4, 2016
Cortical superficial siderosis predicts early recurrent lobar hemorrhageDuangnapa Roongpiboonsopit, Andreas Charidimou, Christopher M William, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 5, 2014
Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutationBella Kaufman, Ronnie Shapira-Frommer, Rita K Schmutzler, et al.
Gynecologic Oncology|January 3, 2016
Efficacy and safety of olaparib monotherapy in germline BRCA1/2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapySusan M Domchek, Carol Aghajanian, Ronnie Shapira-Frommer, et al.
The Lancet. Oncology|June 30, 2019
IPH4102, a first-in-class anti-KIR3DL2 monoclonal antibody, in patients with relapsed or refractory cutaneous T-cell lymphoma: an international, first-in-human, open-label, phase 1 trialMartine Bagot, Pierluigi Porcu, Anne Marie-Cardine, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 28, 2019
Romidepsin Plus Liposomal Doxorubicin Is Safe and Effective in Patients with Relapsed or Refractory T-Cell Lymphoma: Results of a Phase I Dose-Escalation StudyKhoan Vu, Chi-Heng Wu, Chen-Yen Yang, et al.
Blood|March 15, 2003
Acquired FANCA dysfunction and cytogenetic instability in adult acute myelogenous leukemiaM William Lensch, Marc Tischkowitz, Tracy A Christianson, et al.
Pageof 16

Showing results (111-120 of 154) with videos related to

Sort By:
Pageof 16
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|June 19, 2015
Comparison of 2 Carmustine-Containing Regimens in the Rituximab Era: Excellent Outcomes Even in Poor-Risk PatientsPaolo F Caimi, Basem M William, Carlos H Silva Rondon, et al.
British Journal of Haematology|December 7, 2018
Phase I/II study of dasatinib and exploratory genomic analysis in relapsed or refractory non-Hodgkin lymphomaJayadev M Umakanthan, Javeed Iqbal, Connie L Batlevi, et al.
Lancet (London, England)|July 9, 2010
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trialAndrew Tutt, Mark Robson, Judy E Garber, et al.
Lancet (London, England)|July 9, 2010
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trialM William Audeh, James Carmichael, Richard T Penson, et al.
Neurology|October 4, 2016
Cortical superficial siderosis predicts early recurrent lobar hemorrhageDuangnapa Roongpiboonsopit, Andreas Charidimou, Christopher M William, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 5, 2014
Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutationBella Kaufman, Ronnie Shapira-Frommer, Rita K Schmutzler, et al.
Gynecologic Oncology|January 3, 2016
Efficacy and safety of olaparib monotherapy in germline BRCA1/2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapySusan M Domchek, Carol Aghajanian, Ronnie Shapira-Frommer, et al.
The Lancet. Oncology|June 30, 2019
IPH4102, a first-in-class anti-KIR3DL2 monoclonal antibody, in patients with relapsed or refractory cutaneous T-cell lymphoma: an international, first-in-human, open-label, phase 1 trialMartine Bagot, Pierluigi Porcu, Anne Marie-Cardine, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 28, 2019
Romidepsin Plus Liposomal Doxorubicin Is Safe and Effective in Patients with Relapsed or Refractory T-Cell Lymphoma: Results of a Phase I Dose-Escalation StudyKhoan Vu, Chi-Heng Wu, Chen-Yen Yang, et al.
Blood|March 15, 2003
Acquired FANCA dysfunction and cytogenetic instability in adult acute myelogenous leukemiaM William Lensch, Marc Tischkowitz, Tracy A Christianson, et al.
Pageof 16